Half Moon Medical

The company’s second-generation transcatheter mitral valve repair system has been used to treat at least 15 patients in a pilot study across the US, Canada, and Australia. Interim results show significant and sustained reduction in mitral regurgitation without increased pressure gradient across the valve. The technology offers a less invasive alternative for patients with complex anatomy not suitable for existing percutaneous therapies or open-heart surgery.

Presentations of interim data have been made at major cardiology conferences such as New York Valves. The ongoing pilot study aims to enroll approximately 30 patients.

First-in-human procedures were completed successfully as early as January 2021.

The device remains investigational.

No commercial sales or pivotal trial data yet.

No FDA approval yet; still under clinical investigation.

Notable for being fully repositionable and recoverable during deployment.